PTC THERAPEUTICS, INC. (PTCT) Form 8-K — Oct 29, 2026
$PTCTForm 8-KItems 2.02, 7.01, 9.01Filed Oct 29, 2026, 4:10 PM ET0001104659-26-120200Original filing
PTC Therapeutics reported Q3 2026 total revenue of $358 million, including product revenue of $275.9 million — more than double the $131.0 million from a year ago — driven by the Sephience (sepiapterin) launch, which generated $182 million in its first full year on market. The company raised full-year 2026 guidance, increasing product revenue expectations to $960-990 million from $850-950 million and total revenue to $1.29-1.32 billion, and reiterated it is on track for cash flow breakeven this year with $2.1 billion in cash.
Key figures
- Revenue
- 357807000
- Guidance
- FY2026 total revenue raised to $1.29-1.32B; product revenue raised to $960-990M from $850-950M; GAAP R&D+SG&A $775-815M; non-GAAP $680-720M
- Total Debt
- 536268000
- Revenue Yoy
- Q3 total revenue $357.8M vs $211.0M in Q3 2025 (~70% increase)
- Total Assets
- 3207715000
- Cash Position
- 2127918000
- Shares Outstanding
- 83535767
- Gaap rnd q3
- 105400000
- Gaap sga q3
- 80100000
- Emflaza q3 revenue
- 25100000
- Evrysdi royalty q3
- 81700000
- Sephience q3 revenue
- 181900000
- St920 upfront payment
- 111000000
- Translarna q3 revenue
- 48500000
- Product revenue q3 2025
- 130956000
- Product revenue q3 2026
- 275894000
- Sephience active patients
- over 2,000 worldwide
- Loss on debt extinguishment
- 19263000
- St920 contingent milestones
- 100000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.